While a number of biomarkers, such as CK, CK19, GPC3, AFP, VEGF, EGFR, ERCC1, RRM1, TYMS, BRCA1, p53, VIM and Ki-67 are currently available for clinical assessment of tumor behavior, their prognostic value for LT of HCC is not clear. This evidence concerns the gene BRCA1 and neoplasm.